{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-197046","form_type":"8-K","ticker":"AGEN","cik":"0001098972","company_name":"AGENUS INC","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.168666+00:00","generated_at":"2026-05-31T10:40:41.619048+00:00","sec_items":["2.02","5.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Agenus Q2 net loss $54.8M, advances BOT/BAL in CRC; appoints director; files ATM for up to 13.8M shares","bullets":["Q2 net loss $54.8M, revenue $23.5M (incl $22.6M non-cash royalty); cash $93.7M at June 30 vs $76.1M Dec 31.","BOT/BAL in r/r MSS CRC: RECIST ORR 19.4% in selected cohort; 90% 6-month OS; FDA discouraged AA submission; plan to refile with mature data.","NEST-2 neoadjuvant CRC: 56% (5/9) patients achieved complete pathologic responses; 78% had ≥50% tumor reduction.","Appointed Thomas L. Harrison to Board as Class III director; granted option for 7,500 shares vesting over 3 years.","Filed prospectus supplement for ATM offering of up to 13,843,015 shares under existing B. Riley sales agreement."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-197046","json":"https://secwatch.observer/filing/0001193125-24-197046.json","markdown":"https://secwatch.observer/filing/0001193125-24-197046.md","text":"https://secwatch.observer/filing/0001193125-24-197046.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1098972/000119312524197046/0001193125-24-197046-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1098972/000119312524197046/d800799d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:40:41.619048+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"346f5674c1","claim":"Thomas L. Harrison was elected as Class III director at AGENUS INC.","evidence_excerpt":"On August 7, 2024, the Board of Directors (the “Board”) of Agenus elected Thomas L. Harrison to become a Class III director of Agenus with an initial term that expires at Agenus’s annual meeting of stockholders in 2027.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1098972/000119312524197046/0001193125-24-197046-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"elected"},{"label":"Role","value":"Class III director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}